Edgewise Announces Positive Long-Term Sevasemten Data Demonstrating Sustained Functional Stabilization in Becker Muscular Dystrophy Through 3.5 Years of Follow-Up [Yahoo! Finance]
Edgewise Therapeutics, Inc. (EWTX)
Company Research
Source: Yahoo! Finance
– Data reinforce prior clinical findings of sevasemten in Becker, a rare disease with no approved treatments – –The GRAND CANYON placebo-controlled pivotal cohort is on track to readout in 4Q 2026 – BOULDER, Colo. March 10, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today presented at the 2026 MDA Clinical and Scientific Conference, long-term data from its MESA open-label extension study of sevasemten in Becker muscular dystrophy (Becker), a devastating genetic disorder with no approved therapeutic interventions. The data show participants on sevasemten experienced stabilization of function over 3.5 years in marked contrast to the functional decline expected from Becker natural history data. Sevasemten MESA study NSAA score change from baseline "For the first time with an investigational agent, we are seeing long-term data where individuals with Becker are stable in the face of a disease that we have se
Show less
Read more
Impact Snapshot
Event Time:
EWTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EWTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EWTX alerts
High impacting Edgewise Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
EWTX
News
- Why Edgewise Therapeutics Stock Topped the Market on Tuesday [Yahoo! Finance]Yahoo! Finance
- Edgewise Therapeutics (EWTX) had its price target raised by JPMorgan Chase & Co. from $34.00 to $45.00. They now have an "overweight" rating on the stock.MarketBeat
- Edgewise Therapeutics (EWTX) had its "outperform" rating reaffirmed by Wedbush. They now have a $32.00 price target on the stock.MarketBeat
- Why Edgewise Therapeutics (EWTX) Is Up 6.4% After Long-Term Sevasemten Becker Data - And What's Next [Yahoo! Finance]Yahoo! Finance
- Edgewise Therapeutics Talks Phase III Becker Readout, EDG-7500 HCM Data Due in Q2 at Conference [Yahoo! Finance]Yahoo! Finance
EWTX
Earnings
- 2/26/26 - Miss
EWTX
Sec Filings
- 2/26/26 - Form 10-K
- 2/26/26 - Form 8-K
- 2/17/26 - Form SCHEDULE
- EWTX's page on the SEC website